​New PerKit® Products for Antibody Deruxtecan High Loading and Streptavidin-Oligo Conjugation via Click Chemistry

​New PerKit® Products for Antibody Deruxtecan High Loading and Streptavidin-Oligo Conjugation via Click Chemistry

Posted by Yumei Huang, Katie Rodriguez on 19th Nov 2024

We are excited to announce the addition of two unique PerKit® products to our website this week! These products were developed in response to direct customer requests. Since its launch in 2017, PerKit® has grown to include around 50 products, including ADC conjugation kits that are indispensable across various fields. To keep PerKit® at the forefront of customizable bioconjugation, we continually refine protocols, optimize processes, expand product lines, and incorporate the latest advancements in bioconjugation. 

CM11434 Antibody Deruxtecan High Loading Conjugation Kit. 

Trastuzumab Deruxtecan, marketed as Enhertu, typically carries an average of 8 Deruxtecan molecules per antibody (Nakada, T. et al., Bioorg. Med. Chem. Lett., 2016, 26, 1542−1545). Previously, we launched the standard Antibody Deruxtecan Kit (CM11431), which targets 4 Deruxtecan molecules per antibody. This new kit allows for higher drug loading, delivering up to 8 Deruxtecan molecules per antibody—similar to Enhertu. It is recommended to first use our standard kit to evaluate your antibody's tolerance for conjugation. Once validated, this high-loading kit can achieve the desired level of conjugation while minimizing aggregation or precipitation issues. 

Key Features: 

  • Simple and efficient labeling of IgG with Deruxtecan, minimizing toxin exposure. 
  • Includes an enzymatically cleavable GGFG peptide linker. 
  • Delivers an average of 8 Deruxtecan molecules per antibody. 
  • Fast preparation: only 4 hours total, with less than 1 hour of hands-on time. 
  • Includes all necessary reagents and supplies for preparation and purification. 
  • Achieves over 95% conjugation, free from unreacted drugs. 
  • Post-conjugation services available from CellMosaic® for analysis and DAR determination. 

Learn More on the Product Page! 

CM52427 Streptavidin Oligo Conjugation Kit (Single Label via Click Chemistry) 

Streptavidin-biotin binding systems remain the gold standard for protein and nucleic acid detection and purification. While we previously offered a single-label streptavidin-oligo conjugation kit for amine-modified oligos, this new kit is tailored for DBCO-modified oligos. It supports various oligo configurations and lengths, enabling efficient single-label conjugation with azide-activated streptavidin. 

Key Features: 

  • High-quality azide-activated streptavidin for precise single labeling. 
  • Single purification step yielding over 90% streptavidin-oligo conjugates, with the majority being single-labeled (assuming high-quality oligos). 
  • Quick preparation process, completed within a single day. 
  • Stable linkage with an optimized spacer to prevent interference between oligo binding and streptavidin activity. 
  • Includes all necessary reagents, from preparation to purification. 
  • Tailored post-conjugation services available at CellMosaic®. 

Learn More on the Product Page! 

Both new PerKit® products showcase CellMosaic’s commitment to innovation and customer-driven product development. Whether you're looking to create high-loading ADCs or advanced streptavidin-oligo conjugates, these kits provide reliable, efficient, and high-quality solutions. Visit the product pages to learn more about how these tools can support your research and development needs! 

-------------------------------------------- 

About CellMosaic, Inc. 

CellMosaic® Inc. is a Massachusetts-based biotech company dedicated to creating high-quality, innovative, and advanced bioconjugates. Bioconjugates are used broadly as research tools, diagnostic reagents, and a novel modality for drugs. Due to the complexities of the bioconjugation process and requirement of techniques and knowledge across multidisciplinary fields, not many companies are competent to offer high-quality bioconjugation services and to provide high-quality bioconjugates. CellMosaic was established in 2008 to fill this gap and has since spent a lot of research effort on developing innovative linkers, crosslinking technologies, and advanced bioconjugation processes. CellMosaic’s current business is organized into four units: 1) Reagent/kit business commercializing bioconjugate reagents and personalized bioconjugation kits (PerKit®) based on CellMosaic’s advanced bioconjugation processes − many of these PerKits™ are for preparation of advanced bioconjugates by the customer, such as antibody drug conjugates (ADCs), antibody oligo conjugates (AOCs), and single labeled bioconjugates; 2) Custom conjugation services for research bioconjugates; 3) Contract bioconjugate manufacturing focusing on process development, scale-up, and GLP/GMP manufacturing, and 4) AqT® ADC development focusing on licensing and manufacturing next-generation ADCs using super-hydrophilic and high loading AqT® linkers. These four business units complement each other and form an integrated bioconjugation workflow from ideation to commercialization.